Abstract 73P
Background
Trophoblast cell surface antigen 2 (TROP2), or tumor-associated calcium signal transducer 2 TACSTD2, is a transmembrane transducer of intracellular calcium signal involved in tumor cell proliferation. Sacituzumab-govitecan a TROP2-targeting antibody-drug conjugate (ADC), is approved for breast cancer. Implications of TROP2 amplification (amp) in soft tissue sarcoma (STS) are understudied.
Methods
Amp defined by either CNV (Affymetrix single nucleotide polymorphism [SNP] 6.0 array data) or transcriptome (RNA-Seq_v2, log2- transformed RNA-Seq by expectation maximization [RSEM] normalized values) via cBioPortal. Query for amp of “TACSTD2” gene showed 494 samples of STS in 3 cohorts: Sarcoma TCGA, PanCancer Atlas – Cohort1, Sarcoma (MSKCC/Broad, Nat Genet 2010)- Cohort2 and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020) – Cohort3. For Cohort1, we extracted clinical data from TCGA Research Network; analysis of TCGA PanCancer Atlas with 2,922 pan-cancer cases was also evaluated.
Results
Cohort1 (253 patients) included dedifferentiated liposarcoma (DDLPS), myxofibrosarcoma (MFS), malignant peripheral nerve sheath tumor (MPNST), synovial sarcoma (SS), leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma (UPS). 7% (17/253) exhibited amp of TACSTD2/TROP2 glycoprotein. The DDLPS group included 59 samples, with 11 (19 %) patients with amp. DDLPS clinical data included: median age 62 years, 46 patients with retroperitoneum DDLPS, 20.5 cm median size. 22 patients had R0 surgery. For UPS, amp was observed in 3 cases (6%) of 50 patients. For 24 MFS cases, 4% had the amp. Although the cohort was enriched with LMS, only 2% presenting amp. Cohort2 (207 patients) included DDLPS (24.2%). 19 patients (9%) had amp. Cohort3 included 34 patients with either DDLPS or LMS. Of the cohort 9% presented with amp. 3 of 19 patients with DDLPS (16%). PanCancer Atlas consisted of 2,922 samples across 38 cancers. TROP2 amp detected in 32 samples (2 %). Liposarcoma exhibits the highest amp rate followed by bone cancer and breast cancer. These findings corroborate that patients with DDLPS are enriched for the amp.
Conclusions
Our results support prospective analysis of TROP2 amp in DDLPS clinical trials.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Pollack: Financial Interests, Personal, Invited Speaker: SpringWorks; Financial Interests, Personal, Advisory Board: Deciphera, Aadi. B. Vincenzi: Financial Interests, Personal, Invited Speaker: PharmaMar, Deciphera, Boehringer Ingelheim. P. Viveiros: Financial Interests, Personal, Invited Speaker: SpringWorks. All other authors have declared no conflicts of interest.
Resources from the same session
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Numb serves as a prognostic biomarker and promotes lung adenocarcinoma brain metastasis
Presenter: Yanyan Zhao
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Integrin-fibronectin interplay is a pivotal biological and clinical determinant in papillary thyroid carcinoma
Presenter: Domenico Rocco
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Correlation of IL-6 and c-reactive protein levels with the stage, differentiation and types of colorectal cancer
Presenter: MOHAMED MAHBOOB ALI
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis
Presenter: José Leão Mendes
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Assessment of cancer testis antigen 45 for diagnostic and prognostic applications in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Integrative omics workflow identifies credible druggable targets in high-grade serous cancer
Presenter: Taru Muranen
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - Impact of IHC/PCR discordance on immunotherapy (ICI) response in colorectal cancer (CRC) patients and prospects of liquid biopsy (LB) to replace conventional methods: Survival analysis of BLOOMSI trial
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Response of gastric adenocarcinoma to neoadjuvant chemotherapy with respect to the presence or absence of HER2 overexpression: A prospective observational study
Presenter: Pratap Deb
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine
Presenter: Preeti Paliwal
Session: Cocktail & Poster Display session
Resources:
Abstract